source
- Vertex Q1 revenue slightly below forecasts as key drug sales miss estimates, but Alyftrek revenue surgesVertex Pharmaceuticals reported first‑quarter revenue of about $3 billion, falling just short of Wall Street expectations. The modest miss left the stock largely unchanged on the day of the release…
- Expert outlines how to manage common skin and GI side effects of daraxonrasib in pancreatic cancerDr Pant, MD, a professor at MD Anderson Cancer Center, discussed the safety profile of daraxonrasib, a RAS(ON) multi-selective inhibitor being studied in pancreatic ductal adenocarcinoma. The drug…